The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review

Table 2

Univariate analysis for the 2-outcome model of any response versus no response to rituximab therapy. Values expressed as median (range) or proportion (%).

Variable	Any response (𝑛=25)	No response (𝑛=14)	𝑃 value
Age at diagnosis (years)	5 (1–33)	12 (1.9–40)	0.07
Age at transplant (years)	16 (5–48)	30 (5.5–48)	0.09
Male gender	16/25 (64)	6/14 (42.8)	0.31
Time to end stage renal disease (years)	3 (0.16–19)	4 (0.5–12)	0.42
Time to relapse (days)	2 (1–3513)	22 (1–828)	0.13
Deceased donor source	16/25 (64)	10/14 (71.4)	0.73
Serum albumin at relapse	3.25 (1.4–4.4)	2.3 (1.2–3.3)	0.02
Proteinuria at relapse (g/day)	8 (1.1–97.4)	7.64 (2.4–20)	0.98
Plasmapheresis	21 (0–100)	27 (9–133)	0.36
Pretransplant plasmapheresis	7/25 (28)	2/14 (14.4)	0.45
Posttransplant plasmapheresis	24/25 (96)	14/14 (100)	1.00
Rituximab doses	3 (1–6)	4 (2–6)	0.007
Time from transplant to rituximab (days)	150 (4–3543)	276 (65–1050)	0.29
Time from relapse to rituximab (days)	136 (3–1086)	179 (57–1048)	0.32
Diagnosis of PTLD	3/25 (12)	0/14 (0)	0.54
Cyclophosphamide use	2/25 (8)	2/14 (14.4)	0.85
Tacrolimus use	21/25 (84)	9/14 (64.3)	0.84
Mycophenolate mofetil use	24/25 (96)	13/14 (92.8)	1.00